chartexchange

ANAB270521C00045000
ANAB May 21 2027 45.00 Call
optionOPRA

InactiveOct 13, 2026
10.50USD-18.919%(-2.45)10Vol11OI
Loading…
Underlying
Underlying Price
$47.40
Type
Call
Strike
45
Expiration
May 21, 2027
DTE
183d
Moneyness
ITM
Intrinsic
$2.40
ANAB 45 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Nov 20, 20261d$43.10+0.00%21
Nov 20, 20261d$2.50-55.36%115
Dec 18, 202629d$9.00+0.00%11
Jan 15, 202757d——00
Feb 19, 202792d$7.00-64.38%2020
May 21, 2027183d$10.50-18.92%1011
ANAB Nearby Strikes · May 21, 2027
StrikeLastChangeVolOpen IntMoneyness
25 C——00ITM
30 C$22.50+12.50%10ITM
35 C——00ITM
40 C——00ITM
45 C$10.50-18.92%1011ITM
50 C$9.40-23.58%15OTM
55 C$8.00+0.00%22OTM
60 C$7.50+50.00%24OTM
65 C$6.50+0.00%22OTM
70 C——00OTM
75 C$5.00-9.09%1016OTM
ANAB Profile

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio's proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c